二柏柏林通过调节葡萄糖酶来使胰岛素分泌正常化
Chenyang Zhang1, Xuelian Zhang2, Qianrui Zhang1
1Department of Endocrinology, Beijing Diabetes Institute, Beijing Key Laboratory of Diabetes Research and Care, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Diabetes, obesity & metabolism
|October 13, 2025
概括
柏柏林的类似物二柏柏林 (DHB) 通过向葡萄糖激酶 (GCK) 来增强葡萄糖刺激的胰岛素分泌. 这种化合物在糖尿病治疗的临床前模型中显示出改善的生物可用性和疗效.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 生物化学 生物化学
背景情况:
- 柏柏林 (BBR) 以其降血糖效应而闻名,但其生物可用性较差.
- 在葡萄糖调节中BBR的精确分子标仍然不清楚.
- 开发具有改善药理动力学特性和定义目标的BBR类似物对于糖尿病治疗至关重要.
研究的目的:
- 研究BBR模拟物二二 (DHB) 在调节葡萄糖代谢和胰岛素分泌方面的疗效和机制.
- 为了确定DHB的分子点,负责其抗糖尿病作用.
- 评估DHB作为糖尿病的潜在治疗剂.
主要方法:
- 使用MIN6和INS-1胰腺β细胞进行体外研究,以评估细胞活力和葡萄糖刺激胰岛素分泌 (GSIS).
- 在小鼠体内研究包括口服葡萄糖耐受性测试 (GTT) 和胰岛素释放测试 (IRT).
- 分子对接,细胞热转移试验 (CETSA) 和siRNA淘汰实验,以识别和验证药物标.
主要成果:
- 在胰腺β细胞中,DHB显著促进了GSIS.
- 与BBR相比,DHB在小鼠中表现出更好的口服葡萄糖耐受性和胰岛素释放.
- 分子对接和CETSA确定了葡萄糖激酶 (GCK) 作为DHB的直接结合标.
- 在β细胞中,GCK倒置取消了DHB在β细胞中的胰岛素和细胞保护作用.
结论:
- 乙二 (DHB) 是一种具有增强生物可用性和功效的柏的强效模拟物.
- DHB通过直接准和调节葡萄糖激酶 (GCK) 活性来发挥其降糖和胰岛素敏感作用.
- DHB代表了一个有希望的治疗候选人,通过准胰腺β细胞中的GCK来管理糖尿病.
相关概念视频
Hormones Regulating Blood Glucose
6.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
6.4K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.2K
Dipeptidyl Peptidase 4 Inhibitors
587
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
587
Insulin: The Receptor and Signaling Pathways
2.8K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
2.8K
Glucose Homeostasis: Regulation of Blood Glucose
3.9K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
3.9K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
523
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
523


